At Velsera, we’re passionate about paving the way for the future of bioinformatics and regulatory excellence. We collaborated with the BioCompute Object (BCO) community to develop the BCO standard for communicating complex Next Generation Sequencing (NGS) workflows for regulatory review and developed an award-winning app that generates BCOs from complex workflows. The emerging challenge in the world of BBCOs is to demonstrate their interoperability. BCO tools are rapidly evolving, both within and external to the Food & Drug Administration (FDA). We’re excited to take the lead in this journey!
We’re proud to introduce the Velsera Neoantigen Discovery Workflow as a prime example. Our BCO app can automatically generate a BCO from this sophisticated workflow, showcasing regulatory submission best practices and demonstrating how the FDA can harness the power of BCOs for efficient regulatory reviews.
Sharing innovation at FDA Computing Days: The Velsera team is excited to participate in the yearly event where the FDA highlights computational advances. This year, it’s happening on Sept. 12-13, 2023. Our BCO working group, proudly sponsored by the FDA, has submitted a poster and a video as part of the FDA innovation competition. The conference agenda includes a two-hour discussion on ‘Understanding the Landscape of Data Management and Sharing at FDA and NCI (National Cancer Institute).’ Tanya Davidson from NCI will present on using the Cancer Data Research Data Commons to facilitate data sharing.
With Velsera, BioCompute Objects are more than just a concept; they’re a tangible reality. Join us on this exciting journey towards innovation, interoperability, and regulatory excellence!
Are you interested in our BCO work? Reach out to our Science team today! https://www.sevenbridges.com/contact/
